The second, venetoclax, developed by AbbVie and Genentech, binds to BCL-2 and blocks its interaction with other proteins; this gained FDA approval in 2016 for chronic lymphocytic leukaemia (CLL). This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.